Medical treatment for sphincter of oddi dysfunction: can it replace endoscopic sphincterotomy?

World J Gastroenterol. 2012 Apr 14;18(14):1610-5. doi: 10.3748/wjg.v18.i14.1610.

Abstract

Aim: To report the results of a medical management of sphincter of oddi dysfunction (SOD) after an intermediate follow-up period.

Methods: A total of 59 patients with SOD (2 men and 57 women, mean age 51 years old) were included in this prospective study. After medical treatment for one year, the patients were clinically re-evaluated after an average period of 30 mo.

Results: The distribution of the patients according to the Milwaukee's classification was the following: 11 patients were type 1, 34 were type 2 and 14 were type 3. Fourteen patients underwent an endoscopic sphincterotomy (ES) after one year of medical treatment. The median intermediate follow-up period was 29.8 ± 3 mo (3-72 mo). The initial effectiveness of the medical treatment was complete, partial and poor among 50.8%, 13.5% and 35%, respectively, of the patients. At the end of the follow-up period, 37 patients (62.7%) showed more than 50% improvement. The rate of improvement in patients who required ES was not significantly different compared with the patients treated conservatively (64.2% vs 62.2%, respectively).

Conclusion: Our study confirms that conservative medical treatment could be an alternative to endoscopic sphincterotomy because, after an intermediate follow-up period, the two treatments show the same success rates.

Keywords: Biliary scintigraphy; Cholecystectomy; Endoscopic sphincterotomy; Sphincter of oddi dysfunction.

MeSH terms

  • Adult
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Nitrates / therapeutic use*
  • Prospective Studies
  • Sphincter of Oddi Dysfunction / drug therapy*
  • Sphincter of Oddi Dysfunction / surgery
  • Sphincterotomy, Endoscopic
  • Treatment Outcome
  • Trimebutine / therapeutic use*

Substances

  • Gastrointestinal Agents
  • Nitrates
  • Trimebutine